These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19410696)

  • 1. Patient selection criteria and the FLEX Study.
    Herbst RS; Hirsch FR
    Lancet; 2009 May; 373(9674):1497-8. PubMed ID: 19410696
    [No Abstract]   [Full Text] [Related]  

  • 2. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
    Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
    Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
    Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
    Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
    Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging profile of cetuximab in non-small cell lung cancer.
    Ettinger DS
    Lung Cancer; 2010 Jun; 68(3):332-7. PubMed ID: 19783064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab in NSCLC: another trial needed.
    Perrone F
    Lancet Oncol; 2011 Jan; 12(1):3-4. PubMed ID: 21169059
    [No Abstract]   [Full Text] [Related]  

  • 7. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.
    Douillard JY; Pirker R; O'Byrne KJ; Kerr KM; Störkel S; von Heydebreck A; Grote HJ; Celik I; Shepherd FA
    J Thorac Oncol; 2014 May; 9(5):717-24. PubMed ID: 24662454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
    J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC.
    Rasul KI; Kerr DJ
    Nat Rev Clin Oncol; 2009 Sep; 6(9):499-500. PubMed ID: 19707238
    [No Abstract]   [Full Text] [Related]  

  • 10. Onartuzumab ineffective in non-small-cell lung cancer.
    Brower V
    Lancet Oncol; 2017 Feb; 18(2):e66. PubMed ID: 28017663
    [No Abstract]   [Full Text] [Related]  

  • 11. Durvalumab boosts progression-free survival in NSCLC.
    Gourd E
    Lancet Oncol; 2018 Jan; 19(1):e11. PubMed ID: 29175147
    [No Abstract]   [Full Text] [Related]  

  • 12. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
    Pirker R
    Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
    Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
    Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage with erlotinib plus bevacizumab: not in NSCLC.
    Sculier JP; Meert AP; Berghmans T
    Lancet; 2011 May; 377(9780):1810-2. PubMed ID: 21621709
    [No Abstract]   [Full Text] [Related]  

  • 16. [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
    Cortot AB
    Rev Pneumol Clin; 2010 Dec; 66(6):367-74. PubMed ID: 21167447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Consolidation therapy in advanced non-small cell lung cancer].
    Duchnowska R
    Pneumonol Alergol Pol; 2010; 78(6):439-44. PubMed ID: 21077036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?
    Baselga J
    J Clin Oncol; 2004 Mar; 22(5):759-61. PubMed ID: 14990627
    [No Abstract]   [Full Text] [Related]  

  • 20. First-line treatment for advanced non-small-cell lung cancer.
    Laskin JJ; Sandler AB
    Oncology (Williston Park); 2005 Nov; 19(13):1671-6; discussion 1678-80. PubMed ID: 16425521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.